1
|
Oka Y, Abe-Sato K, Tabuse H, Yasukawa Y, Yahara T, Nishimoto T, Kamitani M, Fukunaga T, Ochiai N, Kumasaka-Abe T, Hitaka K, Gunji E, Ohara H, Takeda T, Kojima N, Asami T. Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points. J Med Chem 2024; 67:1406-1420. [PMID: 38214909 DOI: 10.1021/acs.jmedchem.3c01967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2024]
Abstract
Matrix metalloproteinase-7 (MMP-7) has been shown to play an important role in pathophysiological processes such as cancer and fibrosis. We previously discovered selective MMP-7 inhibitors by molecular hybridization and structure-based drug design. However, the systemic clearance (CLtot) of the biologically active lead compound was very high. Because our studies revealed that hepatic uptake by organic anion transporting polypeptide (OATP) was responsible for the high CLtot, we found a novel approach to reducing their uptake based on isoelectric point (IP) values as an indicator for substrate recognition by OATP1B1/1B3. Our "IP shift strategy" to adjust the IP values culminated in the discovery of TP0628103 (18), which is characterized by reduced in vitro OATP-mediated hepatic uptake and in vivo CLtot. Our in vitro-in vivo extrapolation of OATP-mediated clearance and the "IP shift strategy" provide crucial insights for a new medicinal chemistry approach to reducing the systemic clearance of OATP1B1/1B3 substrates.
Collapse
Affiliation(s)
- Yusuke Oka
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Kumi Abe-Sato
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Hideaki Tabuse
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Yoshifumi Yasukawa
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tohru Yahara
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tomohiro Nishimoto
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Masafumi Kamitani
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Takuya Fukunaga
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Nagahiro Ochiai
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tomoko Kumasaka-Abe
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Kosuke Hitaka
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Emi Gunji
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Hiroki Ohara
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Takuya Takeda
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Naoki Kojima
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Taiji Asami
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| |
Collapse
|
2
|
Nishikawa-Shimono R, Kuwabara M, Fujisaki S, Matsuda D, Endo M, Kamitani M, Futamura A, Nomura Y, Yamaguchi-Sasaki T, Yabuuchi T, Yamaguchi C, Tanaka-Yamamoto N, Satake S, Abe-Sato K, Funayama K, Sakata M, Takahashi S, Hirano K, Fukunaga T, Uozumi Y, Kato S, Tamura Y, Nakamori T, Mima M, Mishima-Tsumagari C, Nozawa D, Imai Y, Asami T. Discovery of novel indole derivatives as potent and selective inhibitors of proMMP-9 activation. Bioorg Med Chem Lett 2024; 97:129541. [PMID: 37952596 DOI: 10.1016/j.bmcl.2023.129541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 10/18/2023] [Accepted: 11/03/2023] [Indexed: 11/14/2023]
Abstract
Matrix metalloproteinase-9 (MMP-9) is a secreted zinc-dependent endopeptidase that degrades the extracellular matrix and basement membrane of neurons, and then contributes to synaptic plasticity by remodeling the extracellular matrix. Inhibition of MMP-9 activity has therapeutic potential for neurodegenerative diseases such as fragile X syndrome. This paper reports the molecular design, synthesis, and in vitro studies of novel indole derivatives as inhibitors of proMMP-9 activation. High-throughput screening (HTS) of our internal compound library and subsequent merging of hit compounds 1 and 2 provided compound 4 as a bona-fide lead. X-ray structure-based design and subsequent lead optimization led to the discovery of compound 33, a highly potent and selective inhibitor of proMMP-9 activation.
Collapse
Affiliation(s)
- Rie Nishikawa-Shimono
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Motoi Kuwabara
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Sho Fujisaki
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Daisuke Matsuda
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.
| | - Mayumi Endo
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Masafumi Kamitani
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Aya Futamura
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Yusaku Nomura
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Toru Yamaguchi-Sasaki
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Tetsuya Yabuuchi
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Chitose Yamaguchi
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Nozomi Tanaka-Yamamoto
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Shunya Satake
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Kumi Abe-Sato
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Kosuke Funayama
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Mayumi Sakata
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Shinji Takahashi
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Koga Hirano
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Takuya Fukunaga
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Yoriko Uozumi
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Sayaka Kato
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Yunoshin Tamura
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Tomoaki Nakamori
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Masashi Mima
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Chiemi Mishima-Tsumagari
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Dai Nozawa
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Yudai Imai
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan
| | - Taiji Asami
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.
| |
Collapse
|
3
|
Abe K, Chiba Y, Ide K, Yoshimi A, Asami T, Suda A, Odawara T, Hishimoto A. Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer's Disease Neuroimaging Initiative Database. J Prev Alzheimers Dis 2022; 9:331-337. [PMID: 35543007 DOI: 10.14283/jpad.2022.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
BACKGROUND Matrix metalloproteinase 9 (MMP-9) has been reported to be correlated with declines in hippocampal volume and cognitive function in ApoE4-positive MCI patients. OBJECTIVES The present study was aimed to investigate the effects of plasma matrix MMP-9 on the conversion risk between mild cognitive impairment (MCI) patients with and without ApoE4. DESIGN AND SETTING Retrospective observational study using the data extracted from the Alzheimer's Disease Neuroimaging Initiative database. PARTICIPANTS We included 211 ApoE4-positive MCI subjects (ApoE4+ MCI) and 184 ApoE4-negative MCI subjects (ApoE4- MCI). MEASUREMENTS We obtained demographic and data including plasma MMP-9 levels at baseline and longitudinal changes in Clinical Dementia Rating (CDR) up to 15 years. We compared conversion rates between ApoE4+ MCI and ApoE4- MCI by the Log-rank test and calculated the hazard ratio (HR) for covariates including age, sex, educational attainment, drinking and smoking histories, medications, and plasma MMP-9 levels using a multiple Cox regression analysis of ApoE4+ MCI and ApoE4- MCI. RESULTS No significant differences were observed in baseline plasma MMP-9 levels between ApoE4+ MCI and ApoE4- MCI. High plasma MMP-9 levels increased the conversion risk significantly more than low plasma MMP-9 levels (HR, 2.46 [95% CI, 1.31-4.48]) and middle plasma MMP-9 levels (HR, 1.67 [95% CI, 1.04-2.65]) in ApoE4+ MCI, but not in ApoE4- MCI. CONCLUSION Plasma MMP-9 would be the risk of the future conversion to dementia in ApoE4+ MCI.
Collapse
Affiliation(s)
- K Abe
- Yuhei Chiba, 3-9 Fukuura Kanazawa-Ku Yokohama Kanagawa 236-0004, Japan, Telephone: +81-45-787-2667, FAX: +81-45-783-2540, E-mail:
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Kuzume K, Koizumi M, Kagata Y, Nishimura K, Kuwabara Y, Okamoto M, Asami T, Murakami Y, Yagi Y, Midoro-Horiuti T. A056 HOW TO DRINK MILK - ASSESSMENT OF AN INTERMITTENT ORAL IMMUNOTHERAPY FOR SEVERE MILK ALLERGY. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Kawai T, Mihara Y, Morita M, Ohkubo M, Asami T, Watanabe TM. Quantitation of Cell Membrane Permeability of Cyclic Peptides by Single-Cell Cytoplasm Mass Spectrometry. Anal Chem 2021; 93:3370-3377. [PMID: 33550808 DOI: 10.1021/acs.analchem.0c03901] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Cyclic peptides (CPs) have attracted attention as next-generation drugs because they possess both cell-permeable potential as small molecules and specific affinity similar to antibodies. As intracellular molecules are important targets of CPs, quantitation of the intracellular retention and transmembrane permeability of CPs is necessary for drug development. However, permeated CPs within cells cannot be directly assessed by conventional permeability assays using methods such as artificial membranes and cell monolayers. Here, we propose a new approach using single-cell cytoplasm mass spectrometry (SCC-MS). After cells were incubated with CPs, the cytoplasm was directly collected from a single cell using a microneedle followed by nanoelectrospray ionization mass spectrometry detection of the CPs. The height of the CP peak was plotted against time and fitted with a simple function, y = a(1 - e-bx), to calculate the apparent permeability coefficient (Papp) for both the influx and efflux directions. MCF-7 cells were selected as model cancer cells and cultured with cyclosporin A (CsA) and its demethylated analogs (dmCsA-1, -2, and -3) as model CPs. Papp values (10-6 cm/s) obtained from cells incubated with 50 μM CPs ranged from 0.017 to 0.121 for influx and 0.20 to 1.48 for efflux. The higher efflux ratio was possibly caused by efflux transporters such as P-glycoprotein, a well-known receptor of CsA. The equilibrated intracellular concentration of CPs was estimated to be as low as 4.1-6.8 μM, which showed good consistency with the high efflux ratio. SCC-MS is promising as a reliable permeability assay for next-generation CP-based pharmaceuticals.
Collapse
Affiliation(s)
- Takayuki Kawai
- RIKEN Center for Biosystems Dynamics Research, Suita, Osaka 565-0874, Japan.,Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka 565-0871, Japan
| | - Yasuhiro Mihara
- Research Headquarters, Taisho Pharmaceutical Co., LTD., Saitama-shi, Saitama 331-9530, Japan
| | - Makiko Morita
- RIKEN Center for Biosystems Dynamics Research, Suita, Osaka 565-0874, Japan
| | - Masahiko Ohkubo
- Research Headquarters, Taisho Pharmaceutical Co., LTD., Saitama-shi, Saitama 331-9530, Japan
| | - Taiji Asami
- Research Headquarters, Taisho Pharmaceutical Co., LTD., Saitama-shi, Saitama 331-9530, Japan
| | - Tomonobu M Watanabe
- RIKEN Center for Biosystems Dynamics Research, Suita, Osaka 565-0874, Japan.,Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima City, Hiroshima 734-8553, Japan
| |
Collapse
|
6
|
Nagai H, Kaisho T, Yokoyama K, Asakawa T, Fujita H, Matsumiya K, Noguchi J, Tsuchimori K, Nishizawa N, Kanematsu-Yamaki Y, Dote K, Inooka H, Sakamoto JI, Ohtaki T, Asami T, Takekawa S. Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice. Br J Pharmacol 2017; 175:359-373. [PMID: 29057457 DOI: 10.1111/bph.14077] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 10/13/2017] [Accepted: 10/15/2017] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND AND PURPOSE Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU-mediated anti-obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor-selective agonists. EXPERIMENTAL APPROACH Efficacy and safety were assessed in mice with diet-induced obesity (DIO) and those with leptin-deficient diabetes (ob/ob) through repeated peripheral administration of selective agonists to NMU1 (NMU-6102) and NMU2 (NMU-2084), along with non-selective NMU1/2 agonists (NMU-0002 and NMU-6014). We also performed immunohistochemistry for c-Fos protein expression in the brain to probe their mechanisms of action. KEY RESULTS Although both non-selective NMU1/2 agonists and the NMU2-selective agonist had high efficacy compared with the NMU1-selective agonist, only the NMU2-selective agonist led to relatively low adverse effects, such as diarrhoea, in DIO mice. However, the non-selective NMU1/2 agonist and the NMU1-selective agonist, but not the NMU2-selective agonist, were effective in diabetic ob/ob mice. Mechanistically, NMU2-selective agonists preferentially activate pro-opiomelanocortin neurons in the hypothalamic arcuate nucleus but not in the paraventricular nucleus. CONCLUSIONS AND IMPLICATIONS These results suggest that an NMU2 receptor-selective agonist may be a well-balanced drug for the treatment of obesity and that an NMU1 receptor-selective agonist may also be beneficial for treating obesity and diabetes once its side effects are minimized.
Collapse
Affiliation(s)
- Hiroaki Nagai
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Tomoko Kaisho
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Kotaro Yokoyama
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Tomoko Asakawa
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Hisashi Fujita
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Kouta Matsumiya
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Jiro Noguchi
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Kazue Tsuchimori
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Naoki Nishizawa
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | | | - Katsuko Dote
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Hiroshi Inooka
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | | | - Tetsuya Ohtaki
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Taiji Asami
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Shiro Takekawa
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| |
Collapse
|
7
|
Niida A, Kanematsu-Yamaki Y, Asakawa T, Ishimura Y, Fujita H, Matsumiya K, Nishizawa N, Adachi Y, Mochida T, Tsuchimori K, Yoneyama-Hirozane M, Sakamoto J, Hirabayashi H, Fukui H, Takekawa S, Asami T. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives. Bioorg Med Chem 2017; 26:566-572. [PMID: 29279243 DOI: 10.1016/j.bmc.2017.12.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2017] [Revised: 12/06/2017] [Accepted: 12/07/2017] [Indexed: 11/18/2022]
Abstract
Neuropeptide Y2 receptor (Y2R) agonism is an important anorectic signal and a target of antiobesity drug discovery. Recently, we synthesized a short-length Y2R agonist, PYY-1119 (4-imidazolecarbonyl-[d-Hyp24,Iva25,Pya(4)26,Cha27,36,γMeLeu28,Lys30,Aib31]PYY(23-36), 1) as an antiobesity drug candidate. Compound 1 induced marked body weight loss in diet-induced obese (DIO) mice; however, 1 also induced severe vomiting in dogs at a lower dose than the minimum effective dose administered to DIO mice. The rapid absorption of 1 after subcutaneous administration caused the severe vomiting. Polyethylene glycol (PEG)- and alkyl-modified derivatives of 1 were synthesized to develop Y2R agonists with improved pharmacokinetic profiles, i.e., lower maximum plasma concentration (Cmax) and longer time at maximum concentration (Tmax). Compounds 5 and 10, modified with 20 kDa PEG at the N-terminus and eicosanedioic acid at the Lys30 side chain of 1, respectively, showed high Y2R binding affinity and induced significant body weight reduction upon once-daily administration to DIO mice. Compounds 5 and 10, with their relatively low Cmax and long Tmax, partially attenuated emesis in dogs compared with 1. These results indicate that optimization of pharmacokinetic properties of Y2R agonists is an effective strategy to alleviate emesis induced by Y2R agonism.
Collapse
Affiliation(s)
- Ayumu Niida
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan.
| | - Yoko Kanematsu-Yamaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan.
| | - Tomoko Asakawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshimasa Ishimura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Hisashi Fujita
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Kouta Matsumiya
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Naoki Nishizawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Yusuke Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Taisuke Mochida
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Kazue Tsuchimori
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Mariko Yoneyama-Hirozane
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Junichi Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Hideki Hirabayashi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Hideo Fukui
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Shiro Takekawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa 251-8555, Japan.
| |
Collapse
|
8
|
Kuzume K, Koizumi M, Okamoto M, Nishimura K, Asami T. P329 Utility and safety of the intermittent oral immunotherapy, step-up method, for severe food allergy patients. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Nishizawa N, Niida A, Adachi Y, Kanematsu-Yamaki Y, Masuda Y, Kumano S, Yokoyama K, Noguchi Y, Asakawa T, Hirabayashi H, Amano N, Takekawa S, Ohtaki T, Asami T. Highly potent antiobesity effect of a short-length peptide YY analog in mice. Bioorg Med Chem 2017; 25:5718-5725. [DOI: 10.1016/j.bmc.2017.08.044] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 08/26/2017] [Accepted: 08/27/2017] [Indexed: 01/07/2023]
|
10
|
Nishizawa N, Kanematsu-Yamaki Y, Funata M, Nagai H, Shimizu A, Fujita H, Sakamoto J, Takekawa S, Asami T. A potent neuromedin U receptor 2-selective alkylated peptide. Bioorg Med Chem Lett 2017; 27:4626-4629. [DOI: 10.1016/j.bmcl.2017.09.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2017] [Revised: 09/04/2017] [Accepted: 09/08/2017] [Indexed: 12/16/2022]
|
11
|
Sakamoto K, Shinohara T, Adachi Y, Asami T, Ohtaki T. A novel LRP1-binding peptide L57 that crosses the blood brain barrier. Biochem Biophys Rep 2017; 12:135-139. [PMID: 29090274 PMCID: PMC5645116 DOI: 10.1016/j.bbrep.2017.07.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Revised: 05/26/2017] [Accepted: 07/03/2017] [Indexed: 12/22/2022] Open
Abstract
The blood-brain barrier (BBB) is a major obstacle to drug delivery into the central nervous system (CNS), in particular for macromolecules such as peptides and proteins. However, certain macromolecules can reach the CNS via a receptor-mediated transcytosis (RMT) pathway, and low-density lipoprotein receptor-related protein 1 (LRP1) is one of the promising receptors for RMT. An LRP1 ligand peptide, Angiopep-2, was reported to pass through the BBB and deliver covalently conjugated drugs into the CNS. While conjugation of LRP1 ligands with drugs would be an effective approach for drug delivery to the CNS, no other reliable LRP1 ligands have been reported to date. In this study, we aimed to identify novel LRP1 ligands to further investigate LRP1-mediated RMT. Using phage display technology, we obtained a novel peptide, L57 (TWPKHFDKHTFYSILKLGKH-OH), with an EC50 value of 45 nM for binding to cluster 4 (Ser3332–Asp3779) of LRP1. L57 was stable in mouse plasma for up to 20 min. In situ brain perfusion assay in mice revealed the significantly high BBB permeability of L57. In conclusion, we discovered L57, the first artificial LRP1-binding peptide with BBB permeability. Our findings will contribute to the development of RMT-based drugs for the treatment of CNS diseases. The first artificial LRP1-binding peptide L57 was discovered by phage display. L57 binds the extracellular domain of LRP1 with an EC50 binding value of 24 nM. L57 exhibits brain uptake in in situ brain perfusion and i.v. injection in mice.
Collapse
Affiliation(s)
- Kotaro Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Tokuyuki Shinohara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Yusuke Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Tetsuya Ohtaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| |
Collapse
|
12
|
Kanematsu-Yamaki Y, Nishizawa N, Kaisho T, Nagai H, Mochida T, Asakawa T, Inooka H, Dote K, Fujita H, Matsumiya K, Hirabayashi H, Sakamoto J, Ohtaki T, Takekawa S, Asami T. Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide. J Med Chem 2017; 60:6089-6097. [DOI: 10.1021/acs.jmedchem.7b00330] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Yoko Kanematsu-Yamaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Naoki Nishizawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Tomoko Kaisho
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Hiroaki Nagai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Taisuke Mochida
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Tomoko Asakawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Hiroshi Inooka
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Katsuko Dote
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Hisashi Fujita
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Kouta Matsumiya
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Hideki Hirabayashi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Junichi Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Tetsuya Ohtaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Shiro Takekawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa, 251-8555, Japan
| |
Collapse
|
13
|
Nishizawa N, Niida A, Adachi Y, Masuda Y, Kumano S, Yokoyama K, Asakawa T, Hirabayashi H, Amano N, Takekawa S, Ohtaki T, Asami T. Potent antiobesity effect of a short-length peptide YY-analogue continuously administered in mice. Bioorg Med Chem Lett 2017; 27:3829-3832. [PMID: 28684122 DOI: 10.1016/j.bmcl.2017.06.055] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 06/18/2017] [Accepted: 06/21/2017] [Indexed: 11/25/2022]
Abstract
The gastrointestinal peptide, peptide YY3-36 (PYY3-36) and its shorter peptide analogues have been reported to reduce appetite by activating the neuropeptide Y2 receptor (Y2R), which is associated with obesity and other metabolic diseases. A 14-amino acid PYY analogue, Ac-[d-Pro24,Cha27,28,36,Aib31]PYY(23-36) (3), showed high binding affinity and agonist activity for the Y2R, similar to that of PYY3-36, but had weak anorectic activity upon continuous administration in lean mice. Three amino acid substitutions [Pya(4)26, Aib28, Lys30], which contributed to the decreased hydrophobicity of 3, efficiently increased its anorectic activity. The compound containing these three amino acids, Ac-[d-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys30]PYY(23-36) (22), exerted more potent and durable food intake suppression than that by PYY3-36 in lean mice, as well as excellent Y2R agonist activity (EC50: 0.20nM) and good subcutaneous bioavailability (66.6%). The 11-day continuous administration of 22 at 1mg/kg/day successfully produced antiobese and antidiabetic effects, with more than 20% body weight loss in obese and Type 2 diabetes ob/ob model mice.
Collapse
Affiliation(s)
- Naoki Nishizawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Ayumu Niida
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Yusuke Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Yasushi Masuda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Satoshi Kumano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Kotaro Yokoyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Tomoko Asakawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Hideki Hirabayashi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Nobuyuki Amano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Shiro Takekawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Tetsuya Ohtaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan.
| |
Collapse
|
14
|
Sakamoto K, Kanematsu-Yamaki Y, Kamada Y, Oka M, Ohnishi T, Miwa M, Asami T, Inooka H. Identification of ligand-selective peptidic ActRIIB-antagonists using phage display technology. Biochem Biophys Rep 2017; 11:33-39. [PMID: 28955765 PMCID: PMC5614685 DOI: 10.1016/j.bbrep.2017.06.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Revised: 05/18/2017] [Accepted: 06/07/2017] [Indexed: 01/02/2023] Open
Abstract
ActRIIB (activin receptor type-2B) is an activin receptor subtype constitutively expressed in the whole body, playing a role in cellular proliferation, differentiation, and metabolism. For its various physiological activities, ActRIIB interacts with activin and multiple other ligands including myostatin (MSTN), growth differentiation factor 11 (GDF11), and bone morphogenetic protein 9 (BMP9). Notably, the protein-protein interaction (PPI) between ActRIIB and MSTN negatively controls muscular development. Therefore, this PPI has been targeted for effective treatment of muscle degenerative diseases such as muscular dystrophy and sarcopenia. Here, we report the identification of ligand-selective peptidic ActRIIB-antagonists by phage display technology. Our peptides bound to the extracellular domain of ActRIIB, inhibited PPIs between ActRIIB expressed on the cell surface and its ligands, and subsequently suppressed activation of Smad that serves as the downstream signal of the ActRIIB pathway. Interestingly, these peptidic antagonists displayed different ligand selectivities; the AR2mini peptide inhibited multiple ligands (activin A, MSTN, GDF11, and BMP9), AR9 inhibited MSTN and GDF11, while AR8 selectively inhibited MSTN. This is the first report of artificial peptidic ActRIIB-antagonists possessing ligand-selectivity. Artificial ActRIIB-antagonist peptides were discovered by phage display. These peptides selectively bound to the extracellular domain of ActRIIB. They antagonized ActRIIB expressed on the cell surface. They presented multiple ligand selectivities.
Collapse
Affiliation(s)
- Kotaro Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoko Kanematsu-Yamaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yusuke Kamada
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masahiro Oka
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Toshiyuki Ohnishi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masanori Miwa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hiroshi Inooka
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
15
|
Nishizawa N, Niida A, Masuda Y, Kumano S, Yokoyama K, Hirabayashi H, Amano N, Ohtaki T, Asami T. Antiobesity Effect of a Short-Length Peptide YY Analogue after Continuous Administration in Mice. ACS Med Chem Lett 2017; 8:628-631. [PMID: 28626523 PMCID: PMC5467190 DOI: 10.1021/acsmedchemlett.7b00047] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 05/01/2017] [Indexed: 11/29/2022] Open
Abstract
Gastrointestinal peptides such as peptide YY (PYY) can regulate appetite, which is relevant to the study of obesity. The intraperitoneal bolus administration of PYY3-36 and a 12-amino acid PYY analogue, benzoyl-[Cha27,28,36,Aib31]PYY25-36 (1), showed similar anorectic activity by activating the Y2 receptor (Y2R). However, food intake inhibition and body weight loss were not observed upon continuous subcutaneous administration of 1 with osmotic pumps in diet-induced obese (DIO) mice. N-Terminal elongation of 1, together with amino acid substitution at position 24, led to a hydrophilic 14-amino acid peptide, Ac-[d-Hyp24,Cha27,28,36,Aib31]PYY23-36 (18), that showed higher affinity and more potent agonist activity for Y2R and a robust anorectic activity with potency similar to that of PYY3-36. In addition, the continuous subcutaneous administration of 18 at 0.3 mg/(kg·day) induced significant body weight loss in DIO mice. These results suggest that a short-length PYY analogue can be a lead compound for antiobesity therapy in a sustained-release formulation.
Collapse
Affiliation(s)
- Naoki Nishizawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Ayumu Niida
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Yasushi Masuda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Satoshi Kumano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Kotaro Yokoyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Hideki Hirabayashi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Nobuyuki Amano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Tetsuya Ohtaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| |
Collapse
|
16
|
Umemoto T, Sakamoto K, Fukuda Y, Adachi Y, Tani A, Asami T. A Glutamic Acid Analog Bearing an Ethylenediamine Moiety Promotes the Cytosolic Delivery of TAT Peptides. CHEM LETT 2017. [DOI: 10.1246/cl.170097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Tadashi Umemoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555
| | - Kotaro Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555
| | - Yasunori Fukuda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555
| | - Yusuke Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555
| | - Akiyoshi Tani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555
| |
Collapse
|
17
|
Nishizawa N, Niida A, Masuda Y, Kumano S, Yokoyama K, Hirabayashi H, Amano N, Ohtaki T, Asami T. A Short-Length Peptide YY Analogue with Anorectic Effect in Mice. ACS Omega 2017; 2:2200-2207. [PMID: 30023658 PMCID: PMC6044503 DOI: 10.1021/acsomega.7b00258] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/04/2017] [Accepted: 05/08/2017] [Indexed: 06/08/2023]
Abstract
Peripheral administration of PYY3-36, a fragment of peptide YY (PYY), has been reported to reduce food intake by activating the neuropeptide Y2 receptor (Y2R). An N-terminally truncated PYY analogue, benzoyl-[Ala26,Ile28,31]PYY(25-36) (1), showed a relatively potent agonist activity for Y2R but a weak anorectic activity by intraperitoneal administration (2000 nmol/kg) in lean mice because of its markedly poor biological stability in the mouse serum. Notably, two cyclohexylalanine (Cha) substitutions for Tyr residues at positions 27 and 36 (4) improved the stability in the mouse serum concomitant with enhanced anorectic activity. Further optimization at positions 27, 28, 30, and 31 revealed that 21, containing Cha28 and Aib31 residues, showed a more potent anorectic activity than PYY3-36 at a low dose of 300 nmol/kg. The minimum effective dose by intraperitoneal administration of 21 was 30 nmol/kg (ca. 52 μg/kg) in mice, suggesting the biologic potential of short-length PYY3-36 analogues with a potent anorectic effect.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Taiji Asami
- E-mail: . Phone: +81-466-32-1186. Fax: +81-466-29-4453
| |
Collapse
|
18
|
Niida A, Sasaki S, Yonemori K, Sameshima T, Yaguchi M, Asami T, Sakamoto K, Kamaura M. Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging. Bioorg Med Chem Lett 2017; 27:2757-2761. [PMID: 28457754 DOI: 10.1016/j.bmcl.2017.04.063] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 04/17/2017] [Accepted: 04/19/2017] [Indexed: 11/27/2022]
Abstract
A structure-activity relationship study of a K-Ras(G12D) selective inhibitory cyclic peptide, KRpep-2d was performed. Alanine scanning of KRpep-2d focusing on the cyclic moiety showed that Leu7, Ile9, and Asp12 are the key elements for K-Ras(G12D) selective inhibition of KRpep-2d. The cysteine bridging was also examined to identify the stable analog of KRpep-2d under reductive conditions. As a result, the KRpep-2d analog (12) including mono-methylene bridging showed potent K-Ras(G12D) selective inhibition in both the presence and the absence of dithiothreitol. This means that mono-methylene bridging is an effective strategy to obtain a reduction-resistance analog of parent disulfide cyclic peptides. Peptide 12 inhibited proliferation of K-Ras(G12D)-driven cancer cells significantly. These results gave valuable information for further optimization of KRpep-2d to provide novel anti-cancer drug candidates targeting the K-Ras(G12D) mutant.
Collapse
Affiliation(s)
- Ayumu Niida
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan.
| | - Shigekazu Sasaki
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan
| | - Kazuko Yonemori
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan
| | - Tomoya Sameshima
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan
| | - Masahiro Yaguchi
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan
| | - Taiji Asami
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan
| | - Kotaro Sakamoto
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan.
| | - Masahiro Kamaura
- Research, Takeda Pharmaceutical Company, Ltd., 2-26-1 Muraokahigashi, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
19
|
Adachi Y, Sakimura K, Shimizu Y, Nakayama M, Terao Y, Yano T, Asami T. Potent and selective oxytocin receptor agonists without disulfide bridges. Bioorg Med Chem Lett 2017; 27:2331-2335. [PMID: 28438540 DOI: 10.1016/j.bmcl.2017.04.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Revised: 04/07/2017] [Accepted: 04/11/2017] [Indexed: 12/31/2022]
Abstract
Oxytocin (OT) is a neuropeptide involved in a wide variety of physiological actions, both peripherally and centrally. Many human studies have revealed the potential of OT to treat autism spectrum disorders and schizophrenia. OT interacts with the OT receptor (OTR) as well as vasopressin 1a and 1b receptors (V1aR, V1bR) as an agonist, and agonistic activity for V1aR and V1bR may have a negative impact on the therapeutic effects of OTR agonism in the CNS. An OTR-selective agonistic peptide, FE 202767, in which the structural differences from OT are a sulfide bond instead of a disulfide bond, and N-alkylglycine replacement for Pro at position 7, was reported. However, the effects of amino acid substitutions in OT have not been comprehensively investigated to compare OTR, V1aR, and V1bR activities. This led us to obtain a new OTR-selective analog by comprehensive amino acid substitutions of OT and replacement of the disulfide bond. A systematic amino acid scanning (Ala, Leu, Phe, Ser, Glu, or Arg) of desamino OT (dOT) at positions 2, 3, 4, 5, 7, and 8 revealed the tolerability for the substitution at positions 7 and 8. Further detailed study showed that trans-4-hydroxyproline (trans-Hyp) at position 7 and γ-methylleucine [Leu(Me)] at position 8 were markedly effective for improving receptor selectivity without decreasing the potency at the OTR. Subsequently, a combination of these amino acid substitutions with the replacement of the disulfide bond of dOT analogs with a sulfide bond (carba analog) or an amide bond (lactam analog) yielded several promising analogs, including carba-1-[trans-Hyp7,Leu(Me)8]dOT (14) with a higher potency (7.2pM) at OTR than that of OT and marked selectivity (>10,000-fold) over V1aR and V1bR. Hence, we investigated comprehensive modification of OT and obtained new OT analogs that exhibited high potency at OTR with marked selectivity. These OTR-selective agonists could be useful to investigate OTR-mediated effects on psychiatric disorders.
Collapse
Affiliation(s)
- Yusuke Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Katsuya Sakimura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Yuji Shimizu
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Masaharu Nakayama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Yasuko Terao
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Takahiko Yano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan.
| |
Collapse
|
20
|
Adachi Y, Sakamoto K, Umemoto T, Fukuda Y, Tani A, Asami T. Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides. Bioorg Med Chem 2017; 25:2148-2155. [PMID: 28284862 DOI: 10.1016/j.bmc.2017.02.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Revised: 02/09/2017] [Accepted: 02/10/2017] [Indexed: 10/20/2022]
Abstract
Protein-protein interaction between dedicator of cytokinesis 2 (DOCK2) and Ras-related C3 botulinum toxin substrate 1 (Rac1) is an attractive intracellular target for transplant rejection and inflammatory diseases. Recently, DOCK2-selective inhibitory peptides have been discovered, and conjugation with oligoarginine cell-penetrating peptide (CPP) improved inhibitory activity in a cell migration assay. Although a number of CPPs have been reported, oligoarginine was only one example introduced to the inhibitory peptides. In this study, we aimed to confirm the feasibility of CPP-conjugation approach for DOCK2-inhibitory peptides, and select preferable sequences as CPP moiety. First, we evaluated cell permeability of thirteen known CPPs and partial sequences of influenza A viral protein PB1-F2 using an internalization assay system based on luciferin-luciferase reaction, and then selected four CPPs with efficient cellular uptake. Among four conjugates of these CPPs and a DOCK2-inhibitory peptide, the inhibitory activity of a novel CPP, PB1-F2 fragment 5 (PF5), conjugate was comparable to oligoarginine conjugate and higher than that of the non-conjugated peptide. Finally, internalization assay revealed that oligoarginine and PF5 increased the cellular uptake of inhibitory peptides to the same extent. Hence, we demonstrated that CPP-conjugation approach is applicable to the development of novel anti-inflammatory drugs based on DOCK2 inhibition by investigating both cellular uptake and bioactivity.
Collapse
Affiliation(s)
- Yusuke Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Kotaro Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Tadashi Umemoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Yasunori Fukuda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Akiyoshi Tani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan.
| |
Collapse
|
21
|
Ohnishi T, Sakamoto K, Asami-Odaka A, Nakamura K, Shimizu A, Ito T, Asami T, Ohtaki T, Inooka H. Generation of a novel artificial TrkB agonist, BM17d99, using T7 phage-displayed random peptide libraries. Biochem Biophys Res Commun 2017; 483:101-106. [DOI: 10.1016/j.bbrc.2016.12.186] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 12/29/2016] [Indexed: 11/30/2022]
|
22
|
Sakamoto K, Adachi Y, Komoike Y, Kamada Y, Koyama R, Fukuda Y, Kadotani A, Asami T, Sakamoto JI. Novel DOCK2-selective inhibitory peptide that suppresses B-cell line migration. Biochem Biophys Res Commun 2016; 483:183-190. [PMID: 28039053 DOI: 10.1016/j.bbrc.2016.12.170] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 12/25/2016] [Indexed: 12/13/2022]
Abstract
Dedicator of cytokinesis 2 (DOCK2) is a key molecule for lymphocyte activation and migration. DOCK2 interacts with Ras-related C3 botulinus toxin substrate 1 (Rac1, GTPase) and mediates the GDP-GTP exchange reaction, indicating that inhibitors against protein-protein interaction (PPI) between DOCK2 and Rac1 would be good drug candidates for treating immune-related disorders. Here, we report DOCK2-selective PPI inhibitory peptides discovered using random peptide T7 phage display technology. These peptides inhibited DOCK2 activity at nanomolar concentrations and were delivered to intracellular compartments by combination with cell-penetrating peptide (CPP). Consequently, one peptide, R4-DCpep-2(V2W/K4R/ox)-NH2 (Ac-RRRRCWARYHGYPWCRRRR-NH2), inhibited migration in human B lymphocyte MINO cell line at IC50 = 120 nM. To our knowledge, this is the first report of a DOCK2-selective peptide inhibitor; this study will contribute to the development of novel DOCK2-targeting immunosuppressive drugs.
Collapse
Affiliation(s)
- Kotaro Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
| | - Yusuke Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yusaku Komoike
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yusuke Kamada
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Ryokichi Koyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yasunori Fukuda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Akito Kadotani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Jun-Ichi Sakamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
23
|
Nishizawa N, Takatsu Y, Kumano S, Kiba A, Ban J, Tsutsumi S, Matsui H, Matsumoto SI, Yamaguchi M, Ikeda Y, Kusaka M, Ohtaki T, Itoh F, Asami T. Design and Synthesis of an Investigational Nonapeptide KISS1 Receptor (KISS1R) Agonist, Ac-d-Tyr-Hydroxyproline (Hyp)-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH2 (TAK-448), with Highly Potent Testosterone-Suppressive Activity and Excellent Water Solubility. J Med Chem 2016; 59:8804-8811. [DOI: 10.1021/acs.jmedchem.6b00379] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Naoki Nishizawa
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Yoshihiro Takatsu
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Satoshi Kumano
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Atsushi Kiba
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Junko Ban
- CMC
Center, Takeda Pharmaceutical Company Ltd, Osaka 532-8686, Japan
| | | | - Hisanori Matsui
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Shin-ichi Matsumoto
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Masashi Yamaguchi
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Yukihiro Ikeda
- CMC
Center, Takeda Pharmaceutical Company Ltd, Osaka 532-8686, Japan
| | - Masami Kusaka
- CMC
Center, Takeda Pharmaceutical Company Ltd, Osaka 532-8686, Japan
| | - Tetsuya Ohtaki
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Fumio Itoh
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| | - Taiji Asami
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa 251-8555, Japan
| |
Collapse
|
24
|
Asami T, Nishizawa N, Matsui H, Takatsu Y, Suzuki A, Kiba A, Terada M, Nishibori K, Nakayama M, Ban J, Matsumoto SI, Tarui N, Ikeda Y, Yamaguchi M, Kusaka M, Ohtaki T, Kitada C. Physicochemically and Pharmacokinetically Stable Nonapeptide KISS1 Receptor Agonists with Highly Potent Testosterone-Suppressive Activity. J Med Chem 2014; 57:6105-15. [DOI: 10.1021/jm5005489] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Taiji Asami
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Naoki Nishizawa
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Hisanori Matsui
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihiro Takatsu
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Atsuko Suzuki
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Atsushi Kiba
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Michiko Terada
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Kimiko Nishibori
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Masaharu Nakayama
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Junko Ban
- Pharmaceutical
Production Division, Takeda Pharmaceutical Company Ltd., Osaka 532-8686, Japan
| | - Shin-ichi Matsumoto
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Naoki Tarui
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Yukihiro Ikeda
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Masashi Yamaguchi
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Masami Kusaka
- Pharmaceutical
Production Division, Takeda Pharmaceutical Company Ltd., Osaka 532-8686, Japan
| | - Tetsuya Ohtaki
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Chieko Kitada
- Pharmaceutical
Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
25
|
Koike H, Asami T, Yoshida S, Takahashi N, Inoue Y. A New-Type Photosystem II Inhibitor which Blocks Electron Transport in Water-Oxidation System. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/znc-1989-3-416] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The mode of action of three types of conjugated enamine compounds was investigated by means of thermoluminescence measurement. Cyanoacrylate and 2-(l-ethoxyethylam inom ethylidene)- 4-dodecyl-5,5-dim ethyl-cyclohexane-1,3-dione (ACm12) converted the B-band (30 °C) arising from S2QB
- charge recombination to a downshifted 6 °C-band. This band was proved to be identical with the DCM U-induced Q-band (6 °C) arising from S2QA
- recombination, indicating that these two compounds block QA to QB electron transport. 3-(1-dodecylam inopropyridene)-6- methyl-2H-pyran-2,4-dione (APp12 ), on the other hand, induced an abnormal band peaking at 15 °C between the Q-band and B-band. From the gradual downshift of its peak temperature in titration experiments, this band was assigned to arise from a modified S2QB
- charge pair, in which the properties of either QB
- or S2 is altered. The 15 °C-band showed normal oscillation during the first 2 flashes, but the oscillation was interrupted thereafter. Another therm oluminescence analysis by use of post flash low temperature illumination protocol revealed that APp12 affects neither QA to QB nor QB
2- to PQ electron transport, but specifically blocks S3 to S0 transition. These results indicate that APp12 is a new-type PS II inhibitor.
Collapse
Affiliation(s)
| | - T. Asami
- Chemical Regulation of Biomechanism s Lab., The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama 351-01, Japan
| | - S. Yoshida
- Chemical Regulation of Biomechanism s Lab., The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama 351-01, Japan
| | - N. Takahashi
- Chemical Regulation of Biomechanism s Lab., The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama 351-01, Japan
| | | |
Collapse
|
26
|
Matsui H, Asami T. Effects and therapeutic potentials of kisspeptin analogs: regulation of the hypothalamic-pituitary-gonadal axis. Neuroendocrinology 2014; 99:49-60. [PMID: 24356680 DOI: 10.1159/000357809] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Accepted: 12/07/2013] [Indexed: 11/19/2022]
Abstract
The hypothalamic peptide kisspeptin (metastin), the endogenous ligand of the G protein-coupled receptor KISS1R, plays a critical role in controlling GnRH release from hypothalamic GnRH neurons and thereby regulates hypothalamic-pituitary-gonadal functions. Although the therapeutic potential of kisspeptin is attractive, its susceptibility to proteolytic degradation limits its utility. To overcome this, KISS1R agonists or antagonists as peptide analogs or small molecules have been investigated. Kisspeptin analogs have been most extensively studied by reducing the length of the peptide from the original 54 amino acids to 10 amino acids or less and by substituting key amino acid residues. Also, 2 investigational kisspeptin agonist analogs have been evaluated in clinical studies in men; in agreement with animal studies, abrupt elevations in gonadotropin and testosterone levels were observed as an acute effect, followed by rapid reductions in these hormones as a chronic effect. Some studies of small-molecule KISS1R antagonists have also been published. In this review, we present a brief overview on kisspeptin/KISS1R physiology in reproductive functions and summarize the available knowledge of both agonists and antagonists. We also focus on the kisspeptin agonist analogs by summarizing key pharmacological findings from both clinical and preclinical studies, and discuss their potential therapeutic utility.
Collapse
Affiliation(s)
- Hisanori Matsui
- Extra Value Generation and General Medicine Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | | |
Collapse
|
27
|
Affiliation(s)
- Y. Ujiié
- Department of Biology; Shinshu University; Matsumoto Japan
| | - T. Asami
- Department of Biology; Shinshu University; Matsumoto Japan
| |
Collapse
|
28
|
Asami T, Nishizawa N, Matsui H, Nishibori K, Ishibashi Y, Horikoshi Y, Nakayama M, Matsumoto SI, Tarui N, Yamaguchi M, Matsumoto H, Ohtaki T, Kitada C. Design, synthesis, and biological evaluation of novel investigational nonapeptide KISS1R agonists with testosterone-suppressive activity. J Med Chem 2013; 56:8298-307. [PMID: 24047141 DOI: 10.1021/jm401056w] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Metastin/kisspeptin is a 54 amino acid peptide ligand of the KISS1R receptor and is a critical regulator of GnRH secretion. The N-terminally truncated peptide, metastin(45-54), possesses a 10-fold higher receptor-binding affinity than full-length metastin and agonistic KISS1R activity but is rapidly inactivated in rodent plasma. We have developed a decapeptide analog [D-Tyr(45),D-Trp(47),azaGly(51),Arg(Me)(53)]metastin(45-54) with improved serum stability compared with metastin(45-54) but with decreased KISS1R agonistic activity. Amino acid replacements at positions 45-47 led to an enhancement of KISS1R agonistic activity and metabolic stability. N-terminal truncation resulted in a stable nonapeptide, [D-Tyr(46),D-Pya(4)(47),azaGly(51),Arg(Me)(53)]metastin(46-54), compound 26, which displayed KISS1R binding affinities comparable to metastin(45-54) and had improved serum stability. Compound 26 reduced plasma testosterone in male rats and is the first short-length metastin analog to possess testosterone suppressive activities. Compound 26 has led to the elucidation of investigational analogs TAK-683 and TAK-448, both of which have undergone clinical evaluation for hormone-dependent diseases such as prostate cancer.
Collapse
Affiliation(s)
- Taiji Asami
- Pharmaceutical Research Division, Shonan Research Center, Takeda Pharmaceutical Company Ltd , 2-26-1, Muraoka-Higashi Fujisawa, Kanagawa 251-8555, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Makris N, Preti MG, Asami T, Pelavin P, Campbell B, Papadimitriou GM, Kaiser J, Baselli G, Westin CF, Shenton ME, Kubicki M. Human middle longitudinal fascicle: variations in patterns of anatomical connections. Brain Struct Funct 2013; 218:951-68. [PMID: 22782432 PMCID: PMC3500586 DOI: 10.1007/s00429-012-0441-2] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2012] [Accepted: 06/19/2012] [Indexed: 10/28/2022]
Abstract
Based on high-resolution diffusion tensor magnetic resonance imaging (DTI) tractographic analyses in 39 healthy adult subjects, we derived patterns of connections and measures of volume and biophysical parameters, such as fractional anisotropy (FA) for the human middle longitudinal fascicle (MdLF). Compared to previous studies, we found that the cortical connections of the MdLF in humans appear to go beyond the superior temporal (STG) and angular (AG) gyri, extending to the temporal pole (TP), superior parietal lobule (SPL), supramarginal gyrus, precuneus and the occipital lobe (including the cuneus and lateral occipital areas). Importantly, the MdLF showed a striking lateralized pattern with predominant connections between the TP, STG and AG on the left and TP, STG and SPL on the right hemisphere. In light of the results of the present study, and of the known functional role of the cortical areas interconnected by the MdLF, we suggested that this fiber pathway might be related to language, high order auditory association, visuospatial and attention functions.
Collapse
Affiliation(s)
- N Makris
- Department of Psychiatry, Neurology and Radiology Services, Center for Morphometric Analysis, A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Funatsu Y, Hasegawa N, Namkoong H, Asami T, Fujiwara H, Kimizuka Y, Tasaka S, Ishii M, Saito F, Yagi K, Betsuyaku T, Iwata S. P24 Pharmacokinetics of peramivir in upper and lower airway epithelia and plasma. Int J Antimicrob Agents 2013. [DOI: 10.1016/s0924-8579(13)70269-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Namkoong H, Ishii M, Fujii H, Asami T, Yagi K, Fujiwara H, Saitoh F, Tasaka S, Hasegawa N, Koyasu S, Betsuyaku T. P12 Clarithromycin expands CD11b+Gr–1+ cells to protect against LPS-induced lethal shock and polymicrobial sepsis. Int J Antimicrob Agents 2013. [DOI: 10.1016/s0924-8579(13)70257-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Kimizuka Y, Asami T, Ishii M, Tasaka S, Namkoong H, Fujiwara H, Funatsu Y, Abe T, Iwata S, Sato Y, Betsuyaku T, Hasegawa N. P298 Clinical and radiological features of Mycobacterium avium complex lung disease observed without chemotherapy. Int J Antimicrob Agents 2013. [DOI: 10.1016/s0924-8579(13)70539-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Matsui H, Tanaka A, Yokoyama K, Takatsu Y, Ishikawa K, Asami T, Nishizawa N, Suzuki A, Kumano S, Terada M, Kusaka M, Kitada C, Ohtaki T. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats. Endocrinology 2012; 153:5297-308. [PMID: 23027808 DOI: 10.1210/en.2012-1388] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Metastin/kisspeptin, a hypothalamic peptide, plays a pivotal role in controlling GnRH neurons. Here we studied the effect of chronic sc administration of two kisspeptin analogs, KISS1-305 and TAK-448, on hypothalamic-pituitary-gonadal function in male rats in comparison with a GnRH analogue leuprolide or bilateral orchiectomy (ORX). The prototype polypeptide, KISS1-305 (1-4 nmol/h), caused substantial elevations of plasma LH and testosterone, followed by abrupt reductions of both hormone levels. Notably, testosterone levels were reduced to castrate levels within 3 d and remained depleted throughout the 4-wk dosing period, an effect that was faster and more pronounced than leuprolide (1 nmol/h) dosing. KISS1-305 also reduced genital organ weight more profoundly than leuprolide. In mechanistic studies, chronic KISS1-305 administration only transiently induced c-Fos expression in GnRH neurons, suggesting that GnRH-neural response was attenuated over time. Hypothalamic GnRH content was reduced to 10-20% of control at 3 wk without any changes in Gnrh mRNA expression. Dosing with the investigational peptide TAK-448 was also studied to extend our understanding of hypothalamic-pituitary functions. Similar to ORX, TAK-448 (0.1 nmol/h) depleted testosterone and decreased GnRH content by 4 wk. However, in contrast to ORX, TAK-448 decreased gonadotropin levels in pituitary and plasma samples, implying the suppression of GnRH pulses. These results suggest that chronic administration of kisspeptin analogs disrupts endogenous kisspeptin signals to suppress intrinsic GnRH pulses, perhaps by attenuating GnRH-neural response and inducing continuous GnRH leakage from the hypothalamus. The potential utility of kisspeptin analogs as novel agents to treat hormone-related diseases, including prostate cancer, is discussed.
Collapse
Affiliation(s)
- Hisanori Matsui
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd., Kanagawa, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Yoshida N, Nishizawa N, Matsui H, Moriya Y, Kitada C, Asami T, Matsumoto H. Development and validation of sensitive sandwich ELISAs for two investigational nonapeptide metastin receptor agonists, TAK-448 and TAK-683. J Pharm Biomed Anal 2012; 70:369-77. [DOI: 10.1016/j.jpba.2012.05.033] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2012] [Revised: 05/18/2012] [Accepted: 05/22/2012] [Indexed: 11/15/2022]
|
35
|
Asami T, Nishizawa N, Ishibashi Y, Nishibori K, Horikoshi Y, Matsumoto H, Ohtaki T, Kitada C. Trypsin resistance of a decapeptide KISS1R agonist containing an Nω-methylarginine substitution. Bioorg Med Chem Lett 2012; 22:6328-32. [DOI: 10.1016/j.bmcl.2012.08.087] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Revised: 08/16/2012] [Accepted: 08/23/2012] [Indexed: 11/25/2022]
|
36
|
Kikinis Z, Asami T, Bouix S, Finn CT, Ballinger T, Tworog-Dube E, Kucherlapati R, Kikinis R, Shenton ME, Kubicki M. Reduced fractional anisotropy and axial diffusivity in white matter in 22q11.2 deletion syndrome: a pilot study. Schizophr Res 2012; 141:35-9. [PMID: 22863550 PMCID: PMC3462006 DOI: 10.1016/j.schres.2012.06.032] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2011] [Revised: 06/18/2012] [Accepted: 06/25/2012] [Indexed: 02/03/2023]
Abstract
Individuals with 22q11.2 deletion syndrome (22q11.2DS) evince a 30% incidence of schizophrenia. We compared the white matter (WM) of 22q11.2DS patients without schizophrenia to a group of matched healthy controls using Tract-Based-Spatial-Statistics (TBSS). We found localized reduction of Fractional Anisotropy (FA) and Axial Diffusivity (AD; measure of axonal integrity) in WM underlying the left parietal lobe. No changes in Radial Diffusivity (RD; measure of myelin integrity) were observed. Of note, studies in chronic schizophrenia patients report reduced FA, no changes in AD, and increases in RD in WM. Our findings suggest different WM microstructural pathology in 22q11.2DS than in patients with schizophrenia.
Collapse
Affiliation(s)
- Z. Kikinis
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,USA
| | - T. Asami
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,USA
| | - S. Bouix
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,USA
| | - C. T. Finn
- Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
| | - T. Ballinger
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,USA
| | - E. Tworog-Dube
- Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - R. Kucherlapati
- Department of Genetics, Harvard Medical School, Boston, MA, USA
| | - R. Kikinis
- Surgical Planning Laboratory, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - M. E. Shenton
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,USA
,Surgical Planning Laboratory, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
,Clinical Neuroscience Division, Laboratory of Neuroscience, Department of Psychiatry, VA Boston Healthcare System, Harvard Medical School Brockton, MA, USA
| | - M. Kubicki
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,USA
,Surgical Planning Laboratory, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
,Clinical Neuroscience Division, Laboratory of Neuroscience, Department of Psychiatry, VA Boston Healthcare System, Harvard Medical School Brockton, MA, USA
| |
Collapse
|
37
|
Asami T, Nishizawa N, Ishibashi Y, Nishibori K, Nakayama M, Horikoshi Y, Matsumoto SI, Yamaguchi M, Matsumoto H, Tarui N, Ohtaki T, Kitada C. Serum stability of selected decapeptide agonists of KISS1R using pseudopeptides. Bioorg Med Chem Lett 2012; 22:6391-6. [PMID: 22975302 DOI: 10.1016/j.bmcl.2012.08.069] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Revised: 08/15/2012] [Accepted: 08/17/2012] [Indexed: 11/16/2022]
Abstract
Metastin/kisspeptin, a 54-amino acid peptide, is the ligand of the G-protein-coupled receptor KISS1R which plays a key role in pathways that regulate reproduction and cell migration in many endocrine and gonadal tissues. The N-terminally truncated decapeptide, metastin(45-54), has 3-10 times higher receptor affinity and intracellular calcium ion-mobilizing activity but is rapidly inactivated in serum. In this study we designed and synthesized stable KISS1R agonistic decapeptide analogs with selected substitutions at positions 47, 50, and 51. Replacement of glycine with azaglycine (azaGly) in which the α-carbon is replaced with a nitrogen atom at position 51 improved the stability of amide bonds between Phe(50)-Gly(51) and Gly(51)-Leu(52) as determined by in vitro mouse serum stability studies. Substitution for tryptophan at position 47 with other amino acids such as serine, threonine, β-(3-pyridyl)alanine, and D-tryptophan (D-Trp), produced analogs that were highly stable in mouse serum. D-Trp(47) analog 13 showed not only high metabolic stability but also excellent KISS1R agonistic activity. Other labile peptides may have increased serum stability using amino acid substitution.
Collapse
Affiliation(s)
- Taiji Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Fujisawa, Kanagawa, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Kiyohara C, Washio M, Horiuchi T, Asami T, Ide S, Atsumi T, Kobashi G, Takahashi H, Tada Y. Risk modification byCYP1A1andGSTM1polymorphisms in the association of cigarette smoking and systemic lupus erythematosus in a Japanese population. Scand J Rheumatol 2012; 41:103-9. [DOI: 10.3109/03009742.2011.608194] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
39
|
Kong APS, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GTC, Wong CK, Leung GTC, Lee KF, Yeung CY, Chan JCN. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab 2011; 13:806-13. [PMID: 21492364 DOI: 10.1111/j.1463-1326.2011.01411.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIM To examine the efficacy, safety and tolerability of rivoglitazone, a novel thiazolidinedione (TZD), and explore its effects on glucose and lipid control compared to placebo and pioglitazone in Chinese type 2 diabetic patients who are treatment naÏve or treated with a single oral blood glucose-lowering drug. METHODS This was a double-blind, randomized, placebo- and active-controlled study. A total of 287 Chinese type 2 diabetic patients with suboptimal glycaemic control (defined as HbA1c ≥6.5 to <10% and fasting plasma glucose ≥7 to ≤15 mmol/l) were enrolled. One hundred and seventy-four eligible patients were randomized into one of the five treatment arms for 12 weeks: placebo, pioglitazone 30 mg daily, rivoglitazone of dose 0.5, 1.0 or 1.5 mg daily. In a full set analysis, we used analysis of covariance to compare the primary endpoint defined as change in HbA1c from baseline to week 12/last observation carried forward in the rivoglitazone group at each dose level with the placebo group. RESULTS Changes in HbA1c were -0.11% in the 0.5-mg group; -0.22% in the 1-mg group and -0.17% in the 1.5-mg rivoglitazone group; -0.06% in the 30-mg pioglitazone group and 0.61% in the placebo group. Compared to placebo, changes were significant in all active treatment groups (all p < 0.05). Increase in high-density lipoprotein cholesterol and decrease in triglyceride were observed in the rivoglitazone 1 and 1.5 mg groups, respectively, compared to placebo from baseline to week 12 (p < 0.05). Drug-related oedema was reported in eight patients (7.7%) in all rivoglitazone groups compared to six patients (16.2%) in the pioglitazone group and one patient (3.0%) in the placebo group. CONCLUSIONS Rivoglitazone is an efficacious, safe and well-tolerated TZD which improved glycaemic control in Chinese type 2 diabetic patients up to 3 months.
Collapse
Affiliation(s)
- A P S Kong
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Sugi T, Tada N, Goto S, Eriguchi M, Asami T. P24-1 Feature extraction of EEG under mental calculation by combinational use of support vector machine. Clin Neurophysiol 2010. [DOI: 10.1016/s1388-2457(10)60998-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Nakadera Y, Sutcharit C, Ubukata T, Seki K, Utsuno H, Panha S, Asami T. Enantiomorphs differ in shape in opposite directions between populations. J Evol Biol 2010; 23:2377-84. [PMID: 20825549 DOI: 10.1111/j.1420-9101.2010.02099.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Development is left-right reversed between dextral and sinistral morphs of snails. In sympatry, they share the same gene pool, including polygenes for shell shape. Nevertheless, their shell shapes are not the mirror images of each other. This triggered a debate between hypotheses that argue either for a developmental constraint or for zygotic pleiotropic effects of the polarity gene. We found that dextrals can be wider or narrower than sinistrals depending on the population, contrary to the prediction of invariable deviation under a developmental constraint. If the pleiotropy is solely responsible instead, the mean shape of each morph should change, depending on the frequency of polarity genotype. Our simulations of this mean shape change under zygotic pleiotropy, however, show that the direction of interchiral difference remains the same regardless of genotype frequency. Our results suggest the presence of genetic variation among populations that changes the maternal or zygotic pleiotropic effect of the polarity gene.
Collapse
Affiliation(s)
- Y Nakadera
- Department of Biology, Shinshu University, Matsumoto, Japan
| | | | | | | | | | | | | |
Collapse
|
42
|
Matsui H, Takatsu Y, Tanaka A, Asami T, Nishizawa N, Kiba A, Kumano S, Suzuki A, Kusaka M, Ohtaki T. 251 Potent and efficient testosterone suppression by chronic administration of novel metastin analogues, TAK-448 and TAK-683, in male rats. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71058-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
43
|
Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Takahashi H, Kobashi G. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population. Lupus 2009; 18:630-8. [DOI: 10.1177/0961203309102809] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Cigarette smoking may be associated with an increased risk of systemic lupus erythematosus (SLE), but the underlying mechanism of this association remains unclear. N-acetyltransferase 2 (NAT2) is highly variable and detoxifies aromatic amines, an important class of carcinogens in tobacco smoke. Individuals who possess homozygous polymorphic alleles have a slower rate of metabolic detoxification of aromatic amines. We investigated the relationship of the NAT2 polymorphism to the risk of SLE with special reference to the interaction with cigarette smoking among 152 SLE cases and 427 controls in a female Japanese population. NAT2*4, NAT2*5B, NAT2*6A and NAT2*7B alleles were detected with polymerase chain reaction–restriction fragment length polymorphism. Individuals carrying the *4/*4 genotype are rapid acetylators, whereas those with homozygous non-*4 genotypes have a slow acetylator phenotype. Cigarette smoking was associated with an increased risk of SLE (odds ratio [OR] = 2.26; 95% confidence interval [CI] = 1.46–3.50). The slow acetylator genotype of NAT2 was significantly associated with an increased risk of SLE (OR = 2.34, 95% CI = 1.21–4.52) compared with the rapid acetylator genotype. A gene-environment interaction was suggested, with a combination of the NAT2 slow acetylator genotype and smoking conferring significantly higher risk (OR = 6.44, 95% CI = 3.07–13.52; attributable proportion due to interaction = 0.50, 95% CI = 0.12–0.88), compared with the NAT2 rapid acetylator genotype and no history of smoking. This study suggests that, in this Japanese population, the NAT2 slow acetylator status may be a determinant in susceptibility to SLE.
Collapse
Affiliation(s)
- C Kiyohara
- Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - M Washio
- Department of Community Health and Clinical Epidemiology, St. Mary’s College, Kurume, Japan
| | - T Horiuchi
- Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Tada
- Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - T Asami
- Rehabilitation Center, Saga Medical School Hospital, Saga, Japan
| | - S Ide
- Department of Community Health and Clinical Epidemiology, St. Mary’s College, Kurume, Japan
| | - H Takahashi
- Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - G Kobashi
- Molecular Biostatistics Research Team, Research Center for Charged Particle Therapy, National Institute of Radiological Science, Chiba, Japan
| | | |
Collapse
|
44
|
Sato TJ, Yamamuro O, Hirota K, Shibayama M, Yoshizawa H, Itoh S, Watanabe S, Asami T, Kindo K, Uwatoko Y, Kanaya T. High-intensity and versatile chopper spectrometer project for J-PARC. J of Neutron Res 2008. [DOI: 10.1080/10238160903361082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Asami T, Gittenberger E, Falkner G. Whole-Body Enantiomorphy and Maternal Inheritance of Chiral Reversal in the Pond Snail Lymnaea stagnalis. J Hered 2008; 99:552-7. [DOI: 10.1093/jhered/esn032] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Abstract
Diverse animals exhibit left–right asymmetry in development. However, no example of dimorphism for the left–right polarity of development (whole-body enantiomorphy) is known to persist within natural populations. In snails, whole-body enantiomorphs have repeatedly evolved as separate species. Within populations, however, snails are not expected to exhibit enantiomorphy, because of selection against the less common morph resulting from mating disadvantage. Here we present a unique example of evolutionarily stable whole-body enantiomorphy in snails. Our molecular phylogeny of South-east Asian tree snails in the genus Amphidromus indicates that enantiomorphy has likely persisted as the ancestral state over a million generations. Enantiomorphs have continuously coexisted in every population surveyed spanning a period of 10 years. Our results indicate that whole-body enantiomorphy is maintained within populations opposing the rule of directional asymmetry in animals. This study implicates the need for explicit approaches to disclosure of a maintenance mechanism and conservation of the genus.
Collapse
Affiliation(s)
- C Sutcharit
- Department of Biology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand
| | | | | |
Collapse
|
47
|
Abstract
UNLABELLED Early observations emphasized the possible development of hyponatraemia in hypothyroid children and adults, but recently this has been questioned. AIM To investigate whether hyponatraemia develops in hypothyroid status by examining sodium handling in screening-detected neonates and infants with congenital hypothyroidism (CH). METHODS Serum thyroid-stimulating hormone (TSH), free thyroxine (FT4), sodium (Na), creatinine (Cr), urinary Na, Cr, fractional sodium excretion rate (FENa) and other chemicals were measured before and after L-thyroxine (LT4) replacement therapy in 32 screening-detected CH neonates (11M, 21F) and 16 age-matched control neonates. RESULTS No cases of hyponatraemia were found in the 32 CH neonates. Their serum Na concentrations (139.1 +/- 1.5 mmol/L, ranging from 136 to 142 mmol/L, median 139 mmol/L) were not statistically different from those of 16 control neonates (139.3 +/- 1.3 mmol/L, ranging from 137 to 142 mmol/L, median 139 mmol/L). No correlation was found between serum levels of TSH and FT4 and serum Na or FENa. No significant changes were found in serum Na concentrations in hypothyroid neonates two months after LT4 replacement therapy. The serum Na concentration (139.1 +/- 0.3 mmol/L, n = 25) before treatment did not change statistically (138.9 +/- 0.2 mmol/L, n = 25) two months after LT4 replacement therapy. CONCLUSION As seen in various earlier reports, hyponatraemia can occur in hypothyroid patients, but no causal relationship exists between them. When hyponatraemia is detected in hypothyroid children, it does not seem to be directly related to lack of thyroid hormones and therefore other possible causes should be sought.
Collapse
Affiliation(s)
- T Asami
- Division of Paediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
| | | |
Collapse
|
48
|
Shimomura Y, Harada M, Goto M, Sugo T, Matsumoto Y, Abe M, Watanabe T, Asami T, Kitada C, Mori M, Onda H, Fujino M. Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem 2002; 277:35826-32. [PMID: 12130646 DOI: 10.1074/jbc.m205337200] [Citation(s) in RCA: 129] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
The structurally related orphan G-protein-coupled receptors GPR7 and GPR8 are expressed in the central nervous system, and their ligands have not been identified. Here, we report the identification of the endogenous ligand for both of these receptors. We purified the peptide ligand from porcine hypothalamus using stable Chinese hamster ovary cell lines expressing human GPR8 and cloned the cDNA encoding its precursor protein. The cDNA encodes two forms of the peptide ligand with lengths of 23 and 30 amino acid residues as mature peptides. We designated the two ligands neuropeptide W-23 (NPW23) and neuropeptide W-30 (NPW30). The amino acid sequence of NPW23 is completely identical to that of the N-terminal 23 residues of NPW30. Synthetic NPW23 and NPW30 activated and bound to both GPR7 and GPR8 at similar effective doses. Intracerebroventricular administration of NPW23 in rats increased food intake and stimulated prolactin release. These findings indicate that neuropeptide W is the endogenous ligand for both GPR7 and GPR8 and acts as a mediator of the central control of feeding and the neuroendocrine system.
Collapse
Affiliation(s)
- Yukio Shimomura
- Discovery Research Laboratories I and Discovery Research Laboratories II, Pharmaceutical Research Division, Takeda Chemical Industries Limited, 10 Wadai, Tsukuba, Ibaraki 300-4293, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Fujii R, Yoshida H, Fukusumi S, Habata Y, Hosoya M, Kawamata Y, Yano T, Hinuma S, Kitada C, Asami T, Mori M, Fujisawa Y, Fujino M. Identification of a neuropeptide modified with bromine as an endogenous ligand for GPR7. J Biol Chem 2002; 277:34010-6. [PMID: 12118011 DOI: 10.1074/jbc.m205883200] [Citation(s) in RCA: 114] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We isolated a novel gene in a search of the Celera data base and found that it encoded a peptidic ligand for a G protein-coupled receptor, GPR7 (O'Dowd, B. F., Scheideler, M. A., Nguyen, T., Cheng, R., Rasmussen, J. S., Marchese, A., Zastawny, R., Heng, H. H., Tsui, L. C., Shi, X., Asa, S., Puy, L., and George, S. R. (1995) Genomics 28, 84-91; Lee, D. K., Nguyen, T., Porter, C. A., Cheng, R., George, S. R., and O'Dowd, B. F. (1999) Mol. Brain Res. 71, 96-103). The expression of this gene was detected in various tissues in rats, including the lymphoid organs, central nervous system, mammary glands, and uterus. GPR7 mRNA was mainly detected in the central nervous system and uterus. In situ hybridization showed that the gene encoding the GPR7 ligand was expressed in the hypothalamus and hippocampus of rats. To determine the molecular structure of the endogenous GPR7 ligand, we purified it from bovine hypothalamic tissue extracts on the basis of cAMP production-inhibitory activity to cells expressing GPR7. Through structural analyses, we found that the purified endogenous ligand was a peptide with 29 amino acid residues and that it was uniquely modified with bromine. We subsequently determined that the C-6 position of the indole moiety in the N-terminal Trp was brominated. We believe this is the first report on a neuropeptide modified with bromine and have hence named it neuropeptide B. In in vitro assays, bromination did not influence the binding of neuropeptide B to the receptor.
Collapse
Affiliation(s)
- Ryo Fujii
- Discovery Research Laboratories 1, Pharmaceutical Research Division, Takeda Chemical Industries Ltd., 10 Wadai, Tsukuba, Ibaraki 300-4293, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Iwasaki SI, Asami T, Kageyama I. Ultrastructural study of the precursor to fungiform papillae prior to the arrival of sensory nerves in the fetal rat. J Morphol 2001; 250:225-35. [PMID: 11746462 DOI: 10.1002/jmor.1067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The structure of precursors to fungiform papillae without taste buds, prior to the arrival of sensory nerve fibers at the papillae, was examined in the fetal rat on embryonic day 13 (E13) and 16 (E16) by light and transmission electron microscopy in an attempt to clarify the mechanism of morphogenesis of these papillae. At E13, a row of rudiments of fungiform papillae was arranged along both sides of the median sulcus of the lingual dorsal surface, and each row consisted of about 10 rudiments. There was no apparent direct contact between papillae rudiments and sensory nerves at this time. Bilaterally towards the lateral side of the tongue, adjacent to these first rudiments of fungiform papillae, a series of cord-like invaginations of the dorsal epithelium of the tongue into the underlying connective tissue, representing additional papillary primordia parallel to the first row, was observed. The basal end of each invagination was enlarged as a round bulge, indented at its tip by a mound of fibroblasts protruding into the bulge. At E16 there was still no apparent direct contact between rudiments of fungiform papillae and sensory nerves. Each rudiment apically contained a spherical core of aggregating cells, which consisted of a dense assembly of large, oval cells unlike those in other areas of the lingual dorsal epithelium. The differentiation of these aggregated cells was unclear. The basal lamina was clearly recognizable between the epithelium of the rudiment of fungiform papillae and the underlying connective tissue. Spherical structures, which appeared to be sections of the cord-like invaginations of the lingual epithelium that appeared on E13, were observed within the connective tissue separated from the dorsal lingual epithelium. Transverse sections of such structures revealed four concentric layers of cells: a central core, an inner shell, an outer shell, and a layer of large cells. Bundles of fibers were arranged in the central core, and the diameters of bundles varied somewhat depending on the depth of the primordia within the connective tissue and their distance from the median sulcus. Ultrastructural features of cells in the outer shell differed significantly in rudiments close to the lingual epithelium as compared to those in deeper areas of connective tissue. Around the outer shell there was a large-cell layer consisting of one to three layers of radially elongated, oval cells that contained many variously sized, electron-dense, round granules. Large numbers of fibroblasts formed dense aggregates around each spherical rudiment, and were separated by the basal lamina from the large-cell epithelial layer. Progressing from deep-lying levels of the rudiments of the papillae to levels close to the lingual surface epithelium, the central core, inner shell, and outer shell gradually disappeared from the invaginated papillary cords.
Collapse
Affiliation(s)
- S I Iwasaki
- Advanced Research Center, The Nippon Dental University School of Dentistry at Niigata, 1-8 Hamaura-cho, Niigata 951-8580, Japan.
| | | | | |
Collapse
|